IFM Investors Pty Ltd Acquires 27 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

IFM Investors Pty Ltd grew its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.1% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,285 shares of the biopharmaceutical company’s stock after buying an additional 27 shares during the quarter. IFM Investors Pty Ltd’s holdings in Regeneron Pharmaceuticals were worth $24,478,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its position in Regeneron Pharmaceuticals by 1.0% during the 1st quarter. Vanguard Group Inc. now owns 8,930,241 shares of the biopharmaceutical company’s stock worth $8,595,268,000 after buying an additional 91,956 shares in the last quarter. Capital International Investors raised its holdings in shares of Regeneron Pharmaceuticals by 7.3% in the 1st quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company’s stock valued at $3,011,640,000 after purchasing an additional 213,038 shares during the period. Price T Rowe Associates Inc. MD raised its holdings in shares of Regeneron Pharmaceuticals by 25.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 902,613 shares of the biopharmaceutical company’s stock valued at $868,757,000 after purchasing an additional 184,561 shares during the period. International Assets Investment Management LLC raised its holdings in shares of Regeneron Pharmaceuticals by 86,013.3% in the 3rd quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock valued at $926,078,000 after purchasing an additional 879,916 shares during the period. Finally, Massachusetts Financial Services Co. MA raised its holdings in shares of Regeneron Pharmaceuticals by 12.4% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 540,293 shares of the biopharmaceutical company’s stock valued at $567,864,000 after purchasing an additional 59,769 shares during the period. 83.31% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on REGN. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $1,260.00 target price on shares of Regeneron Pharmaceuticals in a report on Tuesday. JPMorgan Chase & Co. lowered their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating on the stock in a report on Thursday. BMO Capital Markets reissued an “outperform” rating and issued a $1,300.00 price target on shares of Regeneron Pharmaceuticals in a report on Tuesday, September 24th. Barclays lowered their price target on shares of Regeneron Pharmaceuticals from $1,220.00 to $1,080.00 and set an “overweight” rating on the stock in a report on Wednesday. Finally, Wells Fargo & Company lowered their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating on the stock in a report on Tuesday. One research analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $1,101.00.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 487 shares of the firm’s stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total value of $521,090.00. Following the sale, the vice president now owns 4,204 shares in the company, valued at $4,498,280. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 487 shares of the firm’s stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total value of $521,090.00. Following the sale, the vice president now owns 4,204 shares in the company, valued at $4,498,280. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the sale, the chief financial officer now owns 15,305 shares in the company, valued at $18,447,575.65. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN traded down $1.94 during trading hours on Thursday, hitting $939.45. 157,260 shares of the stock were exchanged, compared to its average volume of 502,719. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.62 and a current ratio of 5.44. The company has a market cap of $103.51 billion, a PE ratio of 27.78, a price-to-earnings-growth ratio of 3.40 and a beta of 0.12. The company’s fifty day simple moving average is $1,098.29 and its two-hundred day simple moving average is $1,040.67. Regeneron Pharmaceuticals, Inc. has a 1-year low of $769.19 and a 1-year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $8.93 by $2.63. The business had revenue of $3.55 billion for the quarter, compared to analyst estimates of $3.38 billion. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The firm’s revenue for the quarter was up 12.3% on a year-over-year basis. During the same quarter last year, the business posted $8.79 EPS. On average, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.6 EPS for the current year.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.